Key Milestones
2014
- Establishment of Shenzhen HaploX
2015
- Establishment of Shenzhen Lab
- Launched the Chinese Cancer Sequencing Project to perform early cancer screening for 10,000 people
- Completed the Series Angel Financing
2016
- Certified as National High and New Technology Enterprise
- Completed the Series A Financing
2017
- Establishment of Jiangxi Lab
- Completed the Series A+ Financing
2018
- Certified as Guangdong Tumor Liquid Biopsy Engineering Technology Research Center
- Certified as Innovation and Experiment Center for Postdoctoral Fellows
- Commercialized HapOnco® WESPlus® NGS Assay
- Completed the Series B Financing
- Certified as Operating Base of the High-level Creative Talents Practice Programme of Nanshan District of Shenzhen
2019
- Launched the Liver Exploration Project
- Awarded as 2019 Shenzhen High Tech High Growth Top 20
- Awarded as 2019 Shenzhen Leading Biotech Companies Top 20 Pioneer Enterprise
- Certified as Guangdong New R&D Institution
- Shenzhen Lab obtained the CAP Laboratory Accreditation from the College of American Pathologists
2020
- Establishment of Tianjin Lab
- Commercialized HapOnco® StarPanel™ NGS Assay
- Completed the Series B+ Financing
2021
- HapOnco® LungCDx EGFR/ALK NGS Testing Kit was approved by NMPA as a Class III medical device
- Establishment of Shenzhen Tumor Gene Detection Engineering Technology Center
- Establishment of Shenzhen Academician (Expert) Workstation
- Establishment of Hapmic
- Completed the Series C Financing
2022
- Accompanion software of HapOnco® LungCDx EGFR/ALK NGS Testing Kit approved by Guangdong branch of the NMPA as a Class II medical device
- Establishment of Shenzhen Future Lab
- Awarded as Guangdong Patent Golden Award
- Certified as National Specialized and New 'Small Giant' Enterprise
- Completed the Onshore Series D Financing